PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
450.49%
Net income growth at 75-90% of CRON.TO's 557.92%. Bill Ackman would call for strategic or operational tweaks to match competitor’s earnings growth.
12.61%
D&A growth well above CRON.TO's 17.13%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-2541.17%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
423.14%
SBC growth well above CRON.TO's 28.72%. Michael Burry would flag major dilution risk vs. competitor’s approach.
329.61%
Well above CRON.TO's 162.80% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
109.70%
Well above CRON.TO's 31.47%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
437.30%
Operating cash flow growth above 1.5x CRON.TO's 170.59%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
-407.48%
Both yoy lines negative, with CRON.TO at -247.21%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
-1225.05%
Negative yoy purchasing while CRON.TO stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
No Data
No Data available this quarter, please select a different quarter.
-85.11%
Both yoy lines negative, with CRON.TO at -223571097954720704.00%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-692.42%
Both yoy lines negative, with CRON.TO at -215.54%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
-7.81%
We cut debt repayment yoy while CRON.TO is 100.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
54.21%
Issuance growth of 54.21% while CRON.TO is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.